Skip to main content

Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.

Publication ,  Journal Article
Czito, BG; Willett, CG; Bendell, JC; Morse, MA; Tyler, DS; Fernando, NH; Mantyh, CR; Blobe, GC; Honeycutt, W; Yu, D; Clary, BM; Pappas, TN ...
Published in: J Clin Oncol
February 1, 2006

PURPOSE: Overexpression of epidermal growth factor receptor (EGFR) has been associated with aggressive tumor phenotypes, chemotherapy, and radiation resistance, as well as poor survival in preclinical and clinical models. The EGFR inhibitor gefitinib potentiates chemotherapy and radiation tumor cytotoxicity in preclinical models, including pancreatic and colorectal cancer. We initiated two phase I trials assessing the combination of gefitinib, capecitabine, and radiation in patients with localized pancreatic and rectal cancer. PATIENTS AND METHODS: Patients with pathologically confirmed adenocarcinoma of the pancreas and rectum were eligible. Pretreatment staging included computed tomography, endoscopic ultrasound, and surgical evaluation. Patients received 50.4 Gy of external-beam radiation therapy to the tumor in 28 fractions. Capecitabine and gefitinib were administered throughout the radiation course. Following completion, patients were restaged and considered for resection. Primary end points included determination of dose-limiting toxicity (DLT) and a phase II dose; secondary end points included determination of non-DLTs and preliminary radiographic and pathologic response rates. RESULTS: Ten patients were entered in the pancreatic study and six in the rectal study. DLT was seen in six of 10 patients in the pancreatic study and two of six patients in the rectal study. The primary DLT in both studies was diarrhea. Two patients developed arterial thrombi. CONCLUSION: The combination of gefitinib, capecitabine, and radiation in pancreatic and rectal cancer patients resulted in significant toxicity. A recommended phase II dose was not determined in either of our studies. Further investigation with this combination should be approached with caution.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

February 1, 2006

Volume

24

Issue

4

Start / End Page

656 / 662

Location

United States

Related Subject Headings

  • Rectal Neoplasms
  • Radiotherapy, Adjuvant
  • Quinazolines
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Humans
  • Gefitinib
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Czito, B. G., Willett, C. G., Bendell, J. C., Morse, M. A., Tyler, D. S., Fernando, N. H., … Hurwitz, H. I. (2006). Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol, 24(4), 656–662. https://doi.org/10.1200/JCO.2005.04.1749
Czito, Brian G., Christopher G. Willett, Johanna C. Bendell, Michael A. Morse, Douglas S. Tyler, Nishan H. Fernando, Christopher R. Mantyh, et al. “Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.J Clin Oncol 24, no. 4 (February 1, 2006): 656–62. https://doi.org/10.1200/JCO.2005.04.1749.
Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol. 2006 Feb 1;24(4):656–62.
Czito, Brian G., et al. “Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.J Clin Oncol, vol. 24, no. 4, Feb. 2006, pp. 656–62. Pubmed, doi:10.1200/JCO.2005.04.1749.
Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, Mantyh CR, Blobe GC, Honeycutt W, Yu D, Clary BM, Pappas TN, Ludwig KA, Hurwitz HI. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol. 2006 Feb 1;24(4):656–662.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

February 1, 2006

Volume

24

Issue

4

Start / End Page

656 / 662

Location

United States

Related Subject Headings

  • Rectal Neoplasms
  • Radiotherapy, Adjuvant
  • Quinazolines
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Humans
  • Gefitinib